Actinogen Medical (ASX:ACW) receives FDA approval for six-month phase 2b Alzheimer trial
Actinogen Medical (ACW) has received approval from the US Food and Drug…
Actinogen Medical Limited (ASX:ACW)
About Actinogen Medical Limited
Key Information
ACW In the News
ASX Announcements
| Date | Announcement | File | Views |
|---|---|---|---|
| 15/04/2024 | Price Sensitive PS First patient treated in ACW XanaMIA ph 2b Alzheimers trial | 238.21KB | 3.2K |
| 15/04/2024 | Notification of cessation of securities - ACW | 12.73KB | 173 |
| 05/04/2024 | Appendix 3Y-Mr Malcolm McComas | 193.86KB | 282 |
| 05/04/2024 | Notification of cessation of securities - ACW | 12.77KB | 186 |
| 03/04/2024 | Application for quotation of securities - ACW | 17.11KB | 260 |
| 25/03/2024 | ACW corporate presentation revised licensing slide | 356.48KB | 2.4K |
| 20/03/2024 | Notification of buy-back - ACW | 12.67KB | 348 |
| 20/03/2024 | Actinogen corporate presentation March 2024 | 3.22MB | 688 |